Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ortho Tri-Cyclen LO · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | ACTIVE_COMPARATOR | - |
| B | ACTIVE_COMPARATOR | - |
| C | ACTIVE_COMPARATOR | - |
| D | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Ortho Tri-Cyclen LO | DRUG | Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days. |
| Ortho Cyclen | DRUG | Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days. |
| Ortho Cyclen + Efavirenz | DRUG | Tablet, oral, OC + EFV 600 mg, once daily, 14 days. |
Inclusion Criteria: * Women of childbearing potential with intact ovarian function who have been on a stable method of oral contraceptives for at least 2 months prior to the start of the study. * Documented acceptable Pap smear within 1 year of the start of the study * BMI of 18-32 kg/m² Exclusion...
Top 20 of 28 competitors
Ortho Tri-Cyclen LO is a small molecule drug being studied for use in HIV Infections. It is currently in Phase 1 clinical development. The drug is being investigated for its potential role in the treatment of HIV, though it is not yet approved for this indication.
Ortho Tri-Cyclen LO is developed by Bristol-Myers Squibb Company, which trades under the ticker BMY. The company is conducting clinical research on this drug for the treatment of HIV Infections.
Ortho Tri-Cyclen LO is in Phase 1 clinical development. It is an investigational drug being studied for HIV Infections. The drug is not yet approved and is still undergoing clinical trials to evaluate its safety and potential efficacy.
Ortho Tri-Cyclen LO has one completed clinical trial, NCT00399685, which was a Phase 1 study titled "Drug Interaction - Oral Contraceptive." The trial enrolled 28 female participants in the United States and was active-controlled, though it was not randomized or double-blinded.
Ortho Tri-Cyclen LO is not FDA approved for HIV Infections. It is an investigational drug currently in Phase 1 clinical development. The drug has completed one clinical trial, but it remains under study and has not received regulatory approval for this use.